What is it about?
Ki 67 measured before and after neoadjuvant chemotherapy, and the change might be prognostic factors for overall survival and disease free survival for breast cancer patients. The adjuvant chemotherapy could be chose based on the Ki 67 after neoadjuvant chemotherapy and the change before and after neoadjuvant chemotherapy. The prognostic values of Ki 67 before NAC might be lost in those patients who achieved pCR, but Ki 67 after NAC could be still able to function as prognostic marker. In order to judge the prognosis of breast cancer patients after NAC, combining the Ki 67 level after NAC and the change is the ideal way.
Read the Original
This page is a summary of: Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis, Future Oncology, May 2017, Future Medicine,
You can read the full text:
The following have contributed to this page